Applied DNA Sciences Repositions Pharmacogenomics Testing Service for Indication-Specific Use Cases
Applied DNA Sciences, Inc. (Applied DNA or the “Company”), a pioneer in Polymerase Chain Reaction (PCR)-based DNA technologies, has announced a strategic revamp of its pharmacogenomics testing service, Applied DNA Clinical Labs (ADCL), to cater to tailored subpanels for specific use cases. This shift in go-to-market strategy is aimed at delivering more precise and targeted pharmacogenomics testing.
ADCL’s New Subpanel: Pre-emptive Testing for DPYD Gene Variants
The first subpanel under this new strategy is designed for the pre-emptive testing of patients with genetic variants of the DPYD gene. These variants correlate to potentially reduced or absent DPD enzyme activity, which is essential for metabolizing fluoropyrimidines, namely capecitabine (Xeloda) and fluorouracil (5-FU). These drugs are commonly used in the standard of care treatment for various cancers.
Impact on Individuals
For individuals undergoing chemotherapy treatment with capecitabine or fluorouracil, this new testing strategy could lead to more personalized care. Pre-emptive testing for DPYD gene variants could help doctors identify patients at risk of adverse drug reactions, enabling them to adjust treatment plans accordingly. This could potentially improve treatment outcomes, reduce side effects, and enhance overall patient safety.
Impact on the World
On a larger scale, this strategic shift towards indication-specific pharmacogenomics testing could revolutionize the way healthcare is delivered. By focusing on specific use cases and delivering more precise testing, healthcare providers could make more informed decisions, leading to better patient outcomes and reduced healthcare costs. Additionally, this innovation could pave the way for more widespread adoption of pharmacogenomics testing in clinical settings, ultimately improving the quality of care and advancing the field of personalized medicine.
Conclusion
Applied DNA Sciences’ announcement of tailored subpanels for indication-specific use cases within its pharmacogenomics testing service signifies a significant step towards more precise and personalized care. With the first subpanel targeting DPYD gene variants for pre-emptive testing of patients undergoing treatment with capecitabine and fluorouracil, this strategy could lead to improved treatment outcomes, reduced side effects, and overall enhanced patient safety. The potential global impact of this innovation could be profound, driving advancements in personalized medicine and revolutionizing the way healthcare is delivered.
- Applied DNA Sciences announces strategic revamp of its pharmacogenomics testing service, ADCL
- New go-to-market strategy focuses on tailored subpanels for specific use cases
- First subpanel targets DPYD gene variants for pre-emptive testing of patients with reduced or absent DPD enzyme activity
- Testing could lead to more personalized care, improved treatment outcomes, and reduced side effects
- Potential global impact could drive advancements in personalized medicine and revolutionize healthcare delivery
